Drug Profile
Bowman-Birk Inhibitor Concentrate
Alternative Names: BBI; BBIC; Bowman-Birk InhibitorLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Chymotrypsin inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Orofacial cancer
Most Recent Events
- 06 May 1998 Phase-II clinical trials for Benign prostatic hyperplasia in USA (Unknown route)
- 21 Apr 1997 Phase-II clinical trials for Orofacial cancer in USA (Unknown route)
- 21 Apr 1997 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)